Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedSep 17, 2025
DataAggregated Company Financials
Companies158
  • 7D-1.5%
  • 3M3.0%
  • 1Y-5.5%
  • YTD-1.8%

Over the last 7 days, the Healthcare industry has dropped 1.5%, driven by a pullback from Sectra of 4.6%. In contrast, AddLife has gained 6.5%. Overall the industry is down 5.7% in 12 months. Earnings are forecast to grow by 28% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 17 Sep 2025SEK 607.6bSEK 227.1bSEK 6.6b44.7x92.1x2.7x
Fri, 15 Aug 2025SEK 609.0bSEK 226.8bSEK 6.6b46.4x92.3x2.7x
Sun, 13 Jul 2025SEK 630.8bSEK 226.6bSEK 6.0b44.8x104.7x2.8x
Tue, 10 Jun 2025SEK 632.9bSEK 226.4bSEK 5.8b43.6x108.8x2.8x
Thu, 08 May 2025SEK 590.0bSEK 224.0bSEK 4.8b37.8x121.7x2.6x
Sat, 05 Apr 2025SEK 537.6bSEK 221.5bSEK 5.4b32.5x99.5x2.4x
Mon, 03 Mar 2025SEK 588.0bSEK 206.6bSEK 4.3b35.8x135.6x2.8x
Wed, 29 Jan 2025SEK 584.0bSEK 202.6b-SEK 2,675,858,022.8940.8x-218.3x2.9x
Fri, 27 Dec 2024SEK 577.8bSEK 202.8b-SEK 2,503,902,169.1638.4x-230.7x2.8x
Sun, 24 Nov 2024SEK 506.5bSEK 199.8b-SEK 2,653,445,983.7436.2x-190.9x2.5x
Tue, 22 Oct 2024SEK 596.7bSEK 198.9b-SEK 3,206,372,252.8841.7x-186.1x3x
Thu, 19 Sep 2024SEK 616.7bSEK 200.1b-SEK 2,795,442,136.9440.9x-220.6x3.1x
Sat, 17 Aug 2024SEK 599.0bSEK 199.9b-SEK 2,540,884,670.9841x-235.8x3x
Mon, 15 Jul 2024SEK 585.4bSEK 196.2b-SEK 3,104,678,694.3238.3x-188.5x3x
Wed, 12 Jun 2024SEK 557.0bSEK 195.5b-SEK 3,081,091,991.8535.6x-180.8x2.8x
Fri, 10 May 2024SEK 545.0bSEK 196.8b-SEK 2,715,029,099.5135.5x-200.7x2.8x
Sun, 07 Apr 2024SEK 523.8bSEK 192.8b-SEK 3,173,203,050.4345.6x-165.1x2.7x
Tue, 05 Mar 2024SEK 508.0bSEK 192.2b-SEK 3,659,835,641.3244.4x-138.8x2.6x
Thu, 01 Feb 2024SEK 656.1bSEK 191.7b-SEK 795,100,988.0048.4x-825.1x3.4x
Sat, 30 Dec 2023SEK 542.0bSEK 191.2b-SEK 963,322,468.0048.2x-562.6x2.8x
Mon, 27 Nov 2023SEK 501.3bSEK 190.1b-SEK 1,201,055,298.0050.2x-417.4x2.6x
Wed, 25 Oct 2023SEK 424.7bSEK 186.5b-SEK 1,835,419,558.0034.7x-231.4x2.3x
Fri, 22 Sep 2023SEK 459.7bSEK 185.7b-SEK 2,030,087,413.0036.5x-226.4x2.5x
Sun, 20 Aug 2023SEK 457.5bSEK 185.0b-SEK 1,091,744,910.0037.5x-419.1x2.5x
Tue, 18 Jul 2023SEK 462.9bSEK 179.9b-SEK 1,545,729,692.0044.7x-299.5x2.6x
Thu, 15 Jun 2023SEK 523.3bSEK 178.9b-SEK 772,164,165.0045.9x-677.6x2.9x
Sat, 13 May 2023SEK 518.0bSEK 177.0b-SEK 880,129,490.0042.2x-588.5x2.9x
Mon, 10 Apr 2023SEK 504.0bSEK 172.7b-SEK 1,424,880,805.0035.7x-353.7x2.9x
Wed, 08 Mar 2023SEK 491.6bSEK 172.1b-SEK 1,162,332,437.0038.7x-423x2.9x
Fri, 03 Feb 2023SEK 530.9bSEK 166.7bSEK 282.7m36.1x1877.7x3.2x
Sun, 01 Jan 2023SEK 471.6bSEK 165.7bSEK 699.5m31.9x674.2x2.8x
Tue, 29 Nov 2022SEK 488.0bSEK 165.0bSEK 857.8m31.1x568.9x3x
Thu, 27 Oct 2022SEK 469.6bSEK 160.9b-SEK 25,235,927.0032x-18606.8x2.9x
Sat, 24 Sep 2022SEK 426.0bSEK 159.7b-SEK 211,575,097.0026.4x-2013.4x2.7x
Price to Earnings Ratio

-2013.4x


Total Market Cap: SEK 426.0bTotal Earnings: -SEK 211,575,097.00Total Revenue: SEK 159.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -423x202320242025
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 92.1x which is higher than its 3-year average PE of -423x.
  • The industry is trading close to its 3-year average PS ratio of 2.8x.
Past Earnings Growth
  • Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 12% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-0.54%
Healthcare-1.52%
Life Sciences2.39%
Medical Equipment-0.35%
Biotech-1.01%
Healthcare Services-3.24%
Healthtech-3.62%
Pharma-4.68%
Industry PE
  • Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 29.2%, which is lower than the prior year's growth of 56.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 42% over the next 5 years.
  • However this is lower than its past earnings growth rate of 103% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 20% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ALIF B AddLifeSEK 193.906.5%
+SEK 1.4b		19.0%PE70.1x
EKTA B ElektaSEK 49.466.4%
+SEK 1.1b		-27.4%PE69x
SOBI Swedish Orphan BiovitrumSEK 279.200.9%
+SEK 903.5m		-16.1%PE22.2x
XSPRAY Xspray PharmaSEK 55.6019.1%
+SEK 330.5m		19.1%PB3.9x
RAY B RaySearch LaboratoriesSEK 249.503.5%
+SEK 291.4m		48.5%PE44.3x

Latest News

BONEX
SEK 298.00
Bonesupport Holding
7D
-4.6%
1Y
-7.3%
ORX
SEK 27.80
Orexo
7D
12.1%
1Y
85.8%

There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise

Sep 16
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
EKTA B
SEK 49.46
Elekta
7D
6.4%
1Y
-27.4%

Elekta (STO:EKTA B) Is Due To Pay A Dividend Of SEK1.20

Sep 15
Elekta (STO:EKTA B) Is Due To Pay A Dividend Of SEK1.20
XSPRAY
SEK 55.60
Xspray Pharma
7D
19.1%
1Y
19.1%
SECT B
SEK 311.80
Sectra
7D
-4.6%
1Y
16.9%
INTEG B
SEK 22.55
Integrum
7D
-47.1%
1Y
-21.4%
BIOA B
SEK 270.00
BioArctic
7D
-5.3%
1Y
59.5%
CAMX
SEK 694.00
Camurus
7D
-5.4%
1Y
4.5%

Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery

With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.
RAY B
SEK 249.50
RaySearch Laboratories
7D
3.5%
1Y
48.5%
MCOV B
SEK 259.00
Medicover
7D
-4.4%
1Y
33.0%

Medicover AB (publ) (STO:MCOV B) Not Lagging Industry On Growth Or Pricing

Sep 01
Medicover AB (publ) (STO:MCOV B) Not Lagging Industry On Growth Or Pricing
VICO
SEK 10.06
Vicore Pharma Holding
7D
-14.0%
1Y
41.7%
MCAP
SEK 594.00
MedCap
7D
-3.3%
1Y
20.4%

A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)

Aug 28
A Look At The Intrinsic Value Of MedCap AB (publ) (STO:MCAP)
CINPHA
SEK 17.00
Cinclus Pharma Holding
7D
11.7%
1Y
-40.3%

PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally

Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
ALIF B
SEK 193.90
AddLife
7D
6.5%
1Y
19.0%

Shareholders Should Be Pleased With AddLife AB (publ)'s (STO:ALIF B) Price

Aug 06
Shareholders Should Be Pleased With AddLife AB (publ)'s (STO:ALIF B) Price
SOBI
SEK 279.20
Swedish Orphan Biovitrum
7D
0.9%
1Y
-16.1%

We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt

Aug 04
We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt